NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/10/2025
Voltar para busca
Dado oficial do USPTO
ELLIPSES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
08/10/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
17/08/2021
Data de registro
07/10/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/10/2025
Última transação
08/10/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
MOSCATI,JUSTIN RONALD
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Ellipses Pharma Ltd
Representantes
John C. Cain Munck Wilson Mandala, LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of cancer; veterinary preparations for the treatment of cancer; dietetic preparations for medical purposes; dietetic foods for use in clinical nutrition; food supplements; nutraceuticals for therapeutic and medical purposes; medicated food supplements; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs being preparations; compounds for treating cancer being pharmaceutical preparations; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation to cancer
Classe 42
Medical and pharmacological research services; biological research; clinical research in the field of oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofsurgery in relation to cancer; medical research; providing an online network environment for research and development for drug and pharmaceutical development; providing an online network environment for the designdevelopment and testing of drugs and pharmaceuticals; Providing scientific and technological services and researchanalysisdesign relating thereto; designdevelopment and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research; expert advice relating to drug developmentbeing consulting services in the field of pharmaceutical research; laboratory analysis in the field of pharmaceutical research; computer hardware and software design and development in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; computer network services in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software hosting services in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; software as a service in relation to oncologysurgical oncologyradiation therapychemotherapyhormonal therapyimmunotherapyradiotherapytargeted cancer therapythe preventiondiagnosistreatmentmanagement ofand/or surgery in relation tocancer; Information Technology (IT) consultancyadvisory and information services relating to a network of medical research professionals; scientific advisory services; scientific research projects and studies being scientific research and development; conducting clinical trials being scientific and medical research for others; scientific and medical clinical research for others; clinical research for cancer treatments and pharmaceuticals; providing an online network environment for clinical trials; conducting and collating a research network for treatmentcure and prevention of cancer being medical and scientific research; development of measuring and testing methods being research and development in the field of pharmaceuticals; quality control of services; evaluation of drug development services; industrial testingindustrial design services; pharmaceutical product evaluation; testing of chemicals
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
07/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/10/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/08/2025
PUBO
PUBLISHED FOR OPPOSITION
19/08/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/08/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/07/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
14/05/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/05/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/05/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/05/2025
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
06/01/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/11/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/11/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/05/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
07/05/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
29/12/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/06/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
25/11/2022
GNSL
LETTER OF SUSPENSION E-MAILED
25/11/2022
CNSL
SUSPENSION LETTER WRITTEN
25/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/11/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/05/2022
GNRT
NON-FINAL ACTION E-MAILED
23/05/2022
CNRT
NON-FINAL ACTION WRITTEN
23/05/2022
DOCK
ASSIGNED TO EXAMINER
18/05/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/10/2021
NWAP
NEW APPLICATION ENTERED
20/08/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ELLIPSES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.